15 lines
1.7 KiB
JSON
15 lines
1.7 KiB
JSON
{
|
|
"HubID": "4586",
|
|
"Date": "7/29/2024",
|
|
"HubTags": [
|
|
"External Platform Posts",
|
|
"Future Map Forward Guidance",
|
|
"Future Map"
|
|
],
|
|
"Contacts": "",
|
|
"Companies": "",
|
|
"File": "",
|
|
"Image": "4586__Image_URL.png",
|
|
"Summary": "<p>Looking at a few charts, significant increase in spend has occurred across entitlement spending (social security, medicare, etc). That increase appears concentrated in medicare and medicaid. Are there opportunities to get this under control? Possibly. Cleveland Clinic has a voluntary wellness program that cuts their costs relative to the national average by 38% and rising. 75% of employees participate, and those that do not pay more in healthcare costs. The average Medicare recipient generates expenses (in excess of their premiums) of about $13,730 in 2023; CBO expects that number to reach $22,170 in 2033. If we expanded the Cleveland Clinic program nationwide and cut the 22,170 by 40%, that would be enormous savings right there through voluntary participation in things that everyone can do to improve their health. But the lucky break in reducing health costs could be GLP-1 - that is, Ozempic, Mounjaro, and all GLP-1-related weight loss technology. More than 70% of the U.S. population is classified as obese with direct and indirect costs estimated at $1.7 trillion, not to mention the costs of the industrial food complex to addict you to unhealthy food and then hand you off to the Diabetes Industrial Complex. These drugs could massively disrupt not just the weightloss markets, but the junk food and health care markets, giving us an enormous reduction in health care costs that we never saw coming. </p>",
|
|
"Notes": ""
|
|
} |